12:00 AM
May 07, 2012
 |  BC Week In Review  |  Company News  |  Other News

Shire neurology, dermatology news

Shire disclosed its 1Q12 earnings two legal investigations related to ADHD drugs Adderall XR amphetamine and Vyvanse lisdexamfetamine and to diabetic foot ulcer therapy Dermagraft. On April 5, it received a Civil Investigative Demand (CID) from the U.S. Federal Trade Commission (FTC) requesting the company...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >